Clinical Trials Directory

Trials / Conditions / Primary Peritoneal High Grade Serous Adenocarcinoma

Primary Peritoneal High Grade Serous Adenocarcinoma

13 registered clinical trials studyying Primary Peritoneal High Grade Serous Adenocarcinoma — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
NRG OncologyPhase 3
Active Not RecruitingTesting the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage
NCT05276973
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTesting the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea
NCT04616534
National Cancer Institute (NCI)Phase 1
Active Not RecruitingA Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With
NCT04092270
National Cancer Institute (NCI)Phase 1
Active Not RecruitingTesting the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurr
NCT04034927
National Cancer Institute (NCI)Phase 2
Active Not RecruitingOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cance
NCT03943173
M.D. Anderson Cancer CenterEARLY_Phase 1
Active Not RecruitingNiraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fall
NCT03586661
M.D. Anderson Cancer CenterPhase 1
Active Not RecruitingBevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube
NCT03587311
National Cancer Institute (NCI)Phase 2
WithdrawnBirinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or
NCT02756130
Jonsson Comprehensive Cancer CenterPhase 1 / Phase 2
Active Not RecruitingPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R
NCT02839707
National Cancer Institute (NCI)Phase 2 / Phase 3
Active Not RecruitingNivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
National Cancer Institute (NCI)Phase 2
CompletedRuxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian,
NCT02713386
NRG OncologyPhase 1 / Phase 2
Active Not RecruitingAdavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary P
NCT02659241
M.D. Anderson Cancer CenterEARLY_Phase 1